GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (XPAR:DBV) » Definitions » Cash Received from Insurance Activities

DBV Technologies (XPAR:DBV) Cash Received from Insurance Activities


View and export this data going back to 2012. Start your Free Trial

What is DBV Technologies Cash Received from Insurance Activities?

Cash Received from Insurance Activities only applicable to companies reporting Cash Flow from Operations in direct method.


DBV Technologies Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » DBV Technologies SA (XPAR:DBV) » Definitions » Cash Received from Insurance Activities
Traded in Other Exchanges
Address
177-181 avenue Pierre Brossolette, Montrouge, FRA, 92120
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.